| Literature DB >> 34475758 |
Ya-Fei Qin1,2, Guang-Ming Li1,2, Grace Wang3, De-Jun Kong1,2, Hong-Da Wang1,2, Yi-Ming Zhao1,2, Jing-Peng Hao4, Hong Qin1,2, Da-Qing Sun5, Hao Wang1,2.
Abstract
OBJECTIVE: This study aimed to discover the ceRNAs network in the pathophysiological development of human colorectal cancer (CRC) and to screen biomarkers for target therapy and prognosis by using integrated bioinformatics analysis.Entities:
Keywords: TIMP1; bioinformatic analysis; ceRNAs; circRNAs; colorectal cancer
Year: 2021 PMID: 34475758 PMCID: PMC8407779 DOI: 10.2147/TCRM.S321101
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Clinicopathological Characteristics of 473 CRC Patients
| Clinicopathological Characteristics | Patients (N=473) | |
|---|---|---|
| N | % | |
| Age category (years) | ||
| <65 | 193 | 40.8% |
| ≥65 | 280 | 59.2% |
| Gender | ||
| Female | 212 | 44.8% |
| Male | 261 | 55.2% |
| Pathological Stage | ||
| Stage I | 105 | 22.2% |
| Stage II | 176 | 37.2% |
| Stage III | 124 | 26.2% |
| Stage IV | 68 | 14.4% |
| Pathological T | ||
| Tis | 1 | 0.2% |
| T1 | 10 | 2.1% |
| T2 | 76 | 16.1% |
| T3 | 330 | 69.8% |
| T4 | 56 | 11.8% |
| Pathological N | ||
| N0 | 266 | 56.2% |
| N1 | 128 | 27.1% |
| N2 | 79 | 16.7% |
| Pathological M | ||
| M0 | 363 | 76.7% |
| M1 | 61 | 13.0% |
| Mx | 49 | 10.3% |
| Survival status | ||
| Alive | 375 | 79.3% |
| Dead | 98 | 20.7% |
Figure 1The volcano maps of DEGs between CRC samples and normal samples. (A) A total of 412 DEmRNAs including 82 upregulated and 330 downregulated genes. (B) A total of 260 DEcircRNAs including 253 upregulated and 7 downregulated genes. (C) A total of 190 DEmiRNAs including 82 upregulated and 108 downregulated genes. Red represents upregulated genes and green represents downregulated genes.
Top 10 DEcircRNAs, DEmiRNAs and DEGs in Human CRC
| Symbol | Log Fold Change | P value | Type | |
|---|---|---|---|---|
| circRNAs | hsa_circ_0043278 | 7.35193499 | 1.42E-07 | Up |
| hsa_circ_0072088 | 3.72357337 | 6.43E-06 | Up | |
| hsa_circ_0006174 | 6.97297226 | 2.11E-07 | Up | |
| hsa_circ_0000512 | 6.69347647 | 2.83E-07 | Up | |
| hsa_circ_0000518 | 4.77979328 | 2.11E-06 | Up | |
| hsa_circ_0000511 | 4.62226461 | 2.49E-06 | Up | |
| hsa_circ_0000519 | 6.75758135 | 2.64E-07 | Up | |
| hsa_circ_0005273 | 5.26030064 | 1.27E-06 | Up | |
| hsa_circ_0000520 | 6.94732137 | 2.17E-07 | Up | |
| hsa_circ_0000515 | 5.22840906 | 1.32E-06 | Up | |
| miRNAs | hsa-mir-374a | 7.33005053 | 2.26E-72 | Up |
| hsa-mir-486-2 | −6.0682766 | 1.35E-32 | Down | |
| hsa-mir-142 | 6.04852788 | 1.06E-29 | Up | |
| hsa-mir-486-1 | −6.028201 | 3.42E-31 | Down | |
| hsa-mir-135b | 5.86491219 | 5.52E-22 | Up | |
| hsa-mir-21 | 5.80174888 | 5.68E-114 | Up | |
| hsa-mir-19b-2 | 5.74040834 | 1.35E-40 | Up | |
| hsa-mir-19a | 5.558011 | 1.99E-26 | Up | |
| hsa-mir-139 | −5.4424734 | 2.64E-52 | Down | |
| hsa-mir-328 | −5.4243365 | 3.50E-51 | Down | |
| mRNAs | AQP8 | −6.9967508 | 3.94E-82 | Down |
| CA1 | −6.4593573 | 3.89E-111 | Down | |
| GUCA2A | −6.2382921 | 1.29E-60 | Down | |
| GUCA2B | −6.2006141 | 3.68E-109 | Down | |
| CLCA4 | −6.1925953 | 1.30E-69 | Down | |
| ZG16 | −6.1848044 | 2.71E-52 | Down | |
| SLC26A3 | −5.9938727 | 2.32E-41 | Down | |
| CD177 | −5.894624 | 1.03E-81 | Down | |
| TMIGD1 | −5.6845743 | 6.53E-129 | Down | |
| MS4A12 | −5.6317548 | 1.05E-68 | Down |
Figure 2Functional enrichment analysis of DEmRNAs. (A) The top 9 enrichment scores in GO enrichment analysis of the DEmRNAs including biological process enrichment analysis, cellular components enrichment analysis, molecular function enrichment analysis. (B) The top 16 enrichment scores in KEGG enrichment analysis of the DEmRNAs.
Figure 3The plot of the PPI network of DEmRNAs including 226 nodes and 478 edges by the online database STRING. The combined minimum required interaction score>0.5 was considered statistically significant.
Figure 4Kaplan-Meier survival curves for the top five hub genes including SPP1, CXCL1, TIMP1, CXCL8, and CXCL12. TIMP1 was significantly associated with survival rate of CRC patients.
Figure 5The ceRNAs network of circRNAs-miRNAs-mRNA in CRC. Blue represents DEcircRNAs; Black represents DEmiRNAs; Red represents DEmRNA.
Figure 6The expression levels of DEmRNA and DEmiRNAs in colon cancer patients compared with those of normal samples. (A) The TIMP1 is highly expressed in colon cancer tissue. (B–D) The miR-671-5p, miR-17-3p and miR-328-3p is low expression in colon cancer tissue, **P <0.01, and ***P <0.001.